April 28, 2022
Vifor-Cara Therapeutics’s Kapruvia Approved for Treatment of Moderate-to-Severe Pruritus in Hemodialysis in EU
Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics have announced that the European Commission has granted marketing authorization to Kapruvia (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult hemodialysis patients.
